Proteases catalyse the hydrolyis of peptide bonds in proteins, often in a very precise way, and are thereby involved in the control of a number of important physiological processes including cell-cycle progression, DNA replication, cell proliferation and cell death, as well as the immune response
Protease signalling varies from a simple direct cleavage of a substrate to a complex cascade organization or a protease network, and requires tight regulation
Excessive proteolytic activity often leads to disease but can be prevented by blocking the appropriate proteases, which has been explored therapeutically since the 1950s.
Angiotensin-converting enzyme (ACE) inhibitors, which were introduced in 1981 for the treatment of various cardiovascular diseases (hypertension, heart failure, heart attack and so on), are still the major blockbusters among protease inhibitors on the market. On the other hand, various broad-spectrum matrix metalloprotease (MMP) inhibitors failed in advanced clinical trials for cancer and rheumatoid arthritis treatment in the 1990s because of various drawbacks.
Identification of endogenous protease substrates and other physiological protease ligands is a key issue in understanding protease signalling pathways and an essential part of the identification and validation of protease targets
Therapeutic inhibition of validated protease targets can be achieved either by large or small molecules. Large-molecule approaches include protein-type inhibitors that mimick physiological inhibitors and neutralizing antibodies. The development of small-molecule inhibitors, however, is by far the most popular approach. An ideal inhibitor would be a non-covalent, reversible inhibitor with excellent selectivity, good bioavailability and no side effects. The major issues in inhibitor design are still bioavailability and toxicity.
The most advanced inhibitors in clinical trials are the renin inhibitors aliskiren (SPP100) for the treatment of hypertension and end-organ damage for which an NDA was filed in 2006, and the dipeptidyl peptidase IV (DPP IV) inhibitors sitagliptin (MK-0431) and vildagliptin (LAF 327) for the treatment of type 2 diabetes, for which NDAs were also filed in 2006. Balicatib (AAE581), the most advanced among the cathepsin K inhibitors for osteoporosis treatment, successfully passed Phase II trials in 2005. Diabetes type 2 and osteoporosis are completely new therapeutic areas, which is encouraging for the future.
Proteases, such as kallikrein 3 (prostate-specific antigen) and plasminogen activator, are important diagnostic and prognostic disease markers.
The future of protease-based drug discovery efforts probably lies in the cardiovascular, inflammatory, infectious disease, cancer and neurodegeneration areas.
Until fairly recently, proteases were considered primarily to be protein-degrading enzymes. However, this view has dramatically changed and proteases are now seen as extremely important signalling molecules that are involved in numerous vital processes. Protease signalling pathways are strictly regulated, and the dysregulation of protease activity can lead to pathologies such as cardiovascular and inflammatory diseases, cancer, osteoporosis and neurological disorders. Several small-molecule drugs targeting proteases are already on the market and many more are in development. The status of human protease research and prospects for future protease-targeted drugs are reviewed here, with reference to some key examples where protease drugs have succeeded or failed.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Ultrafast one-minute electronic detection of SARS-CoV-2 infection by 3CLpro enzymatic activity in untreated saliva samples
Nature Communications Open Access 26 October 2022
Nature Communications Open Access 19 October 2022
Scientific Reports Open Access 12 May 2021
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Protein Data Bank
Puente, X. S., Sanchez, L. M., Overall, C. M. & Lopez-Otin, C. Human and mouse proteases: a comparative genomic approach. Nature Rev. Genet. 4, 544–558 (2003).
Rawlings, N. D., Tolle, D. P. & Barrett, A. J. MEROPS: the peptidase database. Nucleic Acids Res. 32 (Database issue), D160–D164 (2004).
Barrett, A. J., Rawlings, N. D. & Woessner, J. F. Jr (eds) Handbook of Proteolytic Enzymes 2nd edn (Academic, Amsterdam, 2004). An essential book for every protease lab. Contains a lot of information about the majority of known proteases from various organisms.
Davie, E. W. & Neurath, H. Identification of a peptide released during autocatalytic activation of trypsinogen. J. Biol. Chem. 212, 515–529 (1955).
Davie, E. W. & Ratnoff, O. D. Waterfall sequence for intrinsic blood clotting. Science 145, 1310–1312 (1964).
MacFarland, R. G. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 202, 498–499 (1964). References 4–6 are classical works describing protease activation by limited proteolysis.
Lopez-Otin, C. & Overall, C. M. Protease degradomics: a new challenge for proteomics. Nature Rev. Mol. Cell Biol. 3, 509–519 (2002). A valuable collection of different approaches for system-wide analysis of proteases.
Thornberry, N. A. et al. A novel heterodimeric cysteine protease is required for interleukin-1b processing in monocytes. Nature 356, 768–774 (1992).
Blobel, C. P. ADAMs: key components in EGFR signalling and development. Nature Rev. Mol. Cell Biol. 6, 32–43 (2005).
Thomas, G. Furin at the cutting edge: from protein traffic to embryiogenesis and disease. Nature Rev. Mol. Cell Biol. 3, 756–766 (2002).
Weihofen, A. & Martoglio, B. Intramembrane-cleaving proteases:controlled liberation of proteins and bioactive peptides. Trends Cell Biol. 13, 71–78 (2003).
Glickman, M. J. & Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373–428 (2002).
Davie, E. W., Fujikawa, K. & Kisiel, W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30, 10363–10370 (1991).
Koblinski, J. E., Ahram, M. & Sloane, B. F. Unraveling the role of proteases in cancer. Clin. Chim. Acta 291, 113–135 (2000).
Stennicke, H. S., Ryan, C. A. & Salvesen, G. S. Reprieval from execution: the molecular basis of caspase inhibition. Trends Biochem. Sci. 27, 94–101 (2002).
Thome, M. et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386, 517–521 (1997).
Cuconati, A. & White, E. Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection. Genes Dev. 16, 2465–2478 (2002).
Gustafsson, D. et al. A new oral anticoagulant: the 50-year challenge. Nature Rev. Drug Discov. 3, 649–659 (2004).
Abbenante, G. & Fairlie, D. P. Protease inhibitors in the clinic. Med. Chem. 1, 71–104 (2005). An excellent collection of the current data on protease inhibitors in clinical and preclinical research.
Rueff, J. & Katus, H. A. New antithrombotic drugs on the horizon. Expert Opin. Investig. Drugs 12, 781–797 (2003).
Hirsch, J. Current anticoagulant therapy — unmet clinical needs. Thromb. Res. 109, S1–S8 (2003).
Zaman, M. A., Oparil, S. & Calhoun, D. A. Drugs targeting the renin–angiotensin–aldosterone system. Nature Rev. Drug Discov. 1, 621–636 (2002).
Acharya, K. R., Sturrock, E. D., Riordan, J. F. & Ehlers, M. R. ACE revisited: a new target for structure-based drug design. Nature Rev. Drug Discov. 2, 891–902 (2003).
Natesh, R., Schwager, S. L., Sturrock, E. D. & Acharya, K. R. Crystal structure of the human angiotensin-converting enzyme–lisinopril complex. Nature 421, 551–554 (2003).
van Esch, J. H. et al. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension 45, 120–125 (2005).
Georgiadis, D. et al. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin. Circ. Res. 93, 148–154 (2003).
Robl, J. A. et al. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem. 40, 1570–1577 (1997).
Kostis, J. B. et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am. J. Hypertens. 17, 103–111 (2004).
Overall, C. M. & Lopez-Otin, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Rev. Cancer 2, 657–672 (2002).
Bergers, G., Javaherian, K., Lo, K. M., Folkman, J. & Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808–812 (1999).
Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387–2392 (2002). An excellent critical analysis of failure of MMP inhibitors in clinical trials.
Neefjes, J. & Dantuma, N. P. Fluorescent probes for proteolysis: tools for drug discovery. Nature Rev. Drug Discov. 3, 58–69 (2004).
Baruch, A., Jeffery, D. A. & Bogyo, M. Enzyme activity — it's all about image. Trends Cell Biol. 14, 29–35 (2004).
Blum, G. et al. Dynamic imaging of protease activity with fluorescently quenched activity based probes. Nature Chem. Biol. 1, 203–209 (2005). A demonstration of in vivo monitoring protease activity in a living mouse, an extremely valuable technique in evaluating the physiological role of a protease in health and disease.
Page, I. H. & Helmer, O. M. A crystalline pressor substance (angiotonin) resulting from the interaction between renin and renin activator. J. Exp. Med. 71, 29 (1940).
Skeggs, L. T., Kahn, J. R. & Shumway, N. P. The preparation and function of the hypertensin-converting enzyme. J. Exp. Med. 103, 295–299 (1956).
Matthews, D. J. & Wells, J. A. Substrate phage: selection of protease substrates by monovalent phage display. Science 260, 1113–1117 (1993). The first report on the use of phage display for determining substrate specificity of a protease.
Harris, J. L., Peterson, E. P., Hudig, D., Thornberry, N. A. & Craik, C. S. Definition and redesign of the extended substrate specificity of granzyme B. J. Biol. Chem. 273, 27364–27373 (1998).
Harris, J. L. et al. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc. Natl Acad. Sci. USA 97, 7754–7759 (2000).
Berger, A. B., Vitorino, P. M. & Bogyo, M. Activity-based protein profiling: applications to biomarker discovery, in vivo imaging and drug discovery. Am. J. Pharmacogenomics 4, 371–381 (2004).
Thornberry, N. A. et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. J. Biol. Chem. 272, 17907–17911 (1997). The first paper to demonstrate the power of combinatorial chemistry in defining the substrate specificity of a protease.
Turk, B. E., Huang, L. L., Piro, E. T. & Cantley, L. C. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nature Biotechnol. 19, 661–667 (2001).
Roberds, S. L. et al. BACE knockout mice are healthy despite lacking the primary b-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10, 1317–1324 (2001). An excellent example of target validation using a mouse knockout model.
Gocheva, V. et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 20, 543–556 (2006). A good example how knockout mice models can be combined with a disease model in order to identify the appropriate targets.
Fingleton, B. Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Des. (in the press).
Yuan, J., Shaham, S., Ledoux, S., Ellis, H. M. & Horvitz, H. M. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1b-converting enzyme. Cell 75, 641–652 (1993).
McQuibban, G. A. et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202–1206 (1999).
Tam, E. M., Morrison, C. J., Wu, Y. I., Stack, S. M. & Overall, C. M. Membrane protease proteomics: isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc. Natl Acad. Sci. USA 101, 6917–6922 (2004).
Bredemeyer, A. J. et al. A proteomic approach for the discovery of protease substrates. Proc. Natl Acad. Sci. USA 101, 11785–11790 (2004).
Van Damme, P. et al. Caspase-specific and nonspecific in vivo protein processing during Fas-induced apoptosis. Nature Meth. 2, 771–777 (2005). This paper demonstrates the power of proteomics in determining in vivo protease substrates.
Medema, J. P. et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16, 2794–2804 (1997).
Reed, J. C. Apoptosis based therapies. Nature Rev. Drug Discov. 1, 111–121 (2002).
Eigenbrot, C. & Kirchhofer, D. New insight into how tissue factor allosterically regulates Factor VIIa. Trends Cardiovasc. Med. 12, 19–26 (2002).
Olson, S. T., Björk, I. & Bock, S. C. Identification of critical molecular interactions mediating heparin activation of antithrombin. Trends Cardiovasc. Med. 12, 198–205 (2002).
Bode, W. & Huber, R. Natural protein proteinase inhibitors and their interaction with proteinases. Eur. J. Biochem. 204, 433–451 (1992).
Bode, W. & Huber, R. Structural basis of the endoproteinase–protein inhibitor interaction. Biochim. Biophys. Acta 1477, 241–252 (2000).
Turk, B., Turk, D. & Salvesen, G. S. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm. Des. 8, 1623–1637 (2002).
Giugliano, R. P. et al. Addition of a tissue-factor/factor VIIa inhibitor to standard treatments in NSTE-ACS managed with an early invasive strategy: results of the phase 2 ANTHEM-TIMI 32 double-blind randomized clinical trial. Am. Heart Assoc. Sci. Sessions Dallas, Texas, USA 13–16 Nov (2005).
Vlasuk, G. P. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation Factor Xa. Thromb. Haemost. 70, 212–216 (1993).
Tuszynski, G. P., Gasic, T. B. & Gasic, G. J. Isolation and characterization of antistasin. J. Biol. Chem. 262, 9718–9723 (1987).
Armstrong, W. B. et al. Clinical modulation of oral leukoplakia and protease activity by Bowman–Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin. Cancer Res. 6, 4684–4691 (2000).
Chen, Y. W., Huang, S. C., Lin-Shiau, S. Y. & Lin, J. K. Bowman–Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis 26, 1296–1306 (2005).
Weimann, L. M. Fully human therapeutic monoclonal antibodies. J. Immunother. 29, 1–9 (2005).
Reuning, U. et al. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr. Pharm. Des. 9, 1529–1543 (2003).
Premzl, A., Zavašnik-Bergant, V., Turk, V. & Kos, J. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp. Cell Res. 283, 206–214 (2003).
Novartis Institute for Tropical Diseases. New technologies for high-throughput screening and lead discovery of anti-viral compounds. Dengue Digest [online], (2005).
McGovern, S. L., Helfand, B. T., Feng, B. & Shoichet, B. K. A specific mechanism of nonspecific inhibition. J. Med. Chem. 46, 4265–4272 (2003).
De Clercq, E. Antiviral drugs in current clinical use. J. Clin. Virol. 30, 115–133 (2004).
Rozman-Pungercˇar, J. et al. Inhibition of papain-like cysteine proteases and legumain by 'caspase-specific' inhibitors: when reaction mechanism is more important than specificity. Cell Death Diff. 10, 881–888 (2003). A good example of the selectivity problems of irreversible protease inhibitors.
Smyth, T. P. Substrate variants versus transition state analogues as noncovalent, reversible enzyme inhibitors. Bioorg. Med. Chem. 12, 4081–4088 (2004).
Thurmond, R. L. et al. Identification of a potent and selective noncovalent cathepsin S inhibitor. J. Pharmacol. Exp. Ther. 308, 268–276 (2004).
Altmann, E., Green, J. & Tintelnot-Blomley, M. Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1′ substituents. Bioorg. Med. Chem. Lett. 13, 1997–2001 (2003).
Hardy, J. A. & Wells, J. A. Searching for new allosteric sites in enzymes. Curr. Opin. Struct. Biol. 14, 706–715 (2004).
Hardy, J. A., Lam, J., Nguyen, J. T., O'Brien, T. & Wells, J. A. Discovery of an allosteric site in the caspases. Proc. Natl Acad. Sci. USA 101, 12461–12466 (2004). Excellent work identifying the first small-molecule allosteric protease inhibitor.
Schimmer, A. D. et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5, 25–35 (2004). The first report demonstrating that potentiating protease activity by inhibiting endogenous protease inhibitors by small molecules can be a useful therapeutic approach.
Bijnens, A. P., Gils, A., Knockaert, I., Stassen, J. M. & Declerck, P. J. Importance of the hinge region between a-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J. Biol. Chem. 275, 6375–6380 (2000).
Rupin, A., Martin, F., Vallez, M. O., Bonhomme, E. & Verbeuren, T. J. Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of platelet-rich thrombus in rat mesenteric arterioles. Thromb. Haemost. 86, 1528–1531 (2001).
Stanton, A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am. J. Cardiovasc. Drugs 3, 389–394 (2003).
Menard, J. et al. Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation 91, 330–338 (1995).
Nussberger, J., Wuerzner, G., Jensen, C. & Brunner, H. R. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 39, E1–E8 (2002).
Wood, J. M., Schnell, C. R., Cumin, F., Menard, J. & Webb, R. L. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and sponataneously hypertensive rats. J. Hypertens. 23, 417–426 (2005).
Mervaala, E. et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 35, 587–594 (2000).
Mentlein, R., Gallwitz, B. & Schmidt, W. E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide glucagon-like peptide-1 (7–36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214, 829–835 (1993).
Kieffer, T. J., McIntosh, C. H. S. & Pederson, R. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136, 3585–3596 (1995).
Marguet, D. et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl Acad. Sci. USA 97, 6874–6879 (2000).
Nagakura, T. et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem. Biophys. Res. Commun. 284, 501–506 (2001).
Deacon, C. F., Ahren, B. & Holst, J. J. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Exp. Opin. Investig. Drugs 13, 1091–1102 (2004).
Nielsen, L. L. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov. Today 10, 703–710 (2005).
Demuth, H. U., McIntosh, C. H. & Pederson, R. A. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors. Biochim. Biophys. Acta 1751, 33–44 (2005).
Augustyns, K., Van der Veken, P., Senten, K. & Haemers, A. The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr. Med. Chem. 12, 971–998 (2005).
Kim, D. et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48, 141–151 (2005).
Augeri, D. J. et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48, 5025–5037 (2005).
Moser, B., Wolf, M., Walz, A. & Loetscher, P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25, 75–84 (2004).
Yan, S., Marguet, D., Dobers, J., Reutter, W. & Fan, H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur. J. Immunol. 33, 1519–1527 (2003).
Gelb, B. D., Shi, G.-P., Chapman, H. A. & Desnick, R. J. Pycnodysostosis is caused by a deficiency of cathepsin K. Science 273, 1236–1238 (1996).
Saftig, P. et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K-deficient mice. Proc. Natl Acad. Sci. USA 95, 13453–13458 (1998).
Gowen, M. et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14, 1654–1663 (1999).
Kiviranta, R. et al. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J. Bone Miner. Res. 16, 1444–1452 (2001).
Inaoka, T. et al. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem. Biophys. Res. Commun. 206, 89–96 (1995).
Grabowska, U., Chambers, T. J. & Shiroo, M. Recent developments in cathepsin K inhibitor design. Curr. Opin. Drug Discov. Devel. 8, 619–630 (2005).
Stroup, G. B. et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J. Bone Miner. Res. 16, 1739–1746 (2001).
Palmer, J. T. et al. Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J. Med. Chem. 48, 7520–7534 (2005).
Turk, D., Guncˇar, G., Podobnik, M. & Turk, B. Revised definition of substrate binding sites of papain-like cysteine proteases. Biol. Chem. 379, 137–147 (1998).
Misbach, M. et al. AAE581, a potent and highly specific cathepsin K inhibitor, prevents bone resorption after oral treatment in rat and monkey. Ann. Mtg Am. Soc. Bone Miner. Res. Nashville, Tennessee, USA 23–27 Sept (2005).
Falgueyret, J. P. et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J. Med. Chem. 48, 7535–7543 (2005).
Deaton, D. N. & Kumar, S. Cathepsin K inhibitors: their potential as anti-osteoporosis agents. Progr. Med. Chem. 42, 245–375 (2004). Excellent review paper focused on the development of cathepsin K inhibitors, which contains useful general information about medicinal chemistry.
Tavares, F. X., Deaton, D. N., Miller, A. B., Miller, L. R. & Wright, L. L. Ketoheterocycle-based inhibitors of cathepsin K: a novel entry into the synthesis of peptidic ketoheterocycles. Bioorg. Med. Chem. Lett. 15, 3891–3895 (2005).
Brown, S. et al. Potent and selective mechanism-based inhibition of gelatinases. J. Am. Chem. Soc. 122, 6799–6800 (2000).
Krüger, A. et al. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res. 65, 3523–3526 (2005).
Gu, Z. et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J. Neurosci. 25, 6401–6408 (2005).
Ikejiri, M. et al. Potent mechanism-based inhibitors for matrix metalloproteinases. J. Biol. Chem. 280, 33992–34002 (2005).
Look, M. P. & Foekens, J. A. Clinical relevance of the urokinase plasminogen activator system in breast cancer. Acta Pathol. Microbiol. Immunol. Scand. 107, 150–159 (1999).
Dixon, S. C., Knopf, K. B. & Figg, W. D. The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol. Rev. 53, 73–91 (2001).
Kos, J. & Lah, T. T. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer. Oncol. Rep. 5, 1349–1361 (1998).
Lai, W. T., Chang, C. H., Tang, Y., Bronson, R. & Tung, C. H. Early diagnosis of osteoarthritis using cathepsin B sensitive near-infrared fluorescent probes. Osteoar. Cartil. 12, 239–244 (2004).
Cazzulo, J. J., Stoka, V. & Turk, V. The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease. Curr. Pharm. Des. 7, 1143–1156 (2001).
Schechter, I. & Berger, A. On the size of the active site of proteinases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157–162 (1967).
Enari, M. et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391, 43–50 (1998).
Rawson, R. B. et al. Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs. Mol. Cell 1, 47–57 (1997).
Wilkinson, K. D. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin. Cell. Dev. Biol. 11, 141–148 (2000).
Turk, D. et al. Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J. 20, 6570–6582 (2001).
Silverman, G. A. et al. The serpins are an expanding superfamily of structurally similar but funtionally diverse proteins: evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276, 33293–33296 (2001).
Stubbs, M. T. et al. The refined 2.4Å X-ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. EMBO J. 9, 1939–1947 (1990).
Gomis-Ruth, F. X. et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 389, 77–81 (1997).
Shiozaki, E. N. et al. Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell 11, 519–527 (2003).
Deveraux, Q., Takahashi, R., Salvesen, G. S. & Reed, J. C. X-linked IAP is a direct inhibitor of cell death proteases. Nature 388, 300–304 (1997).
Turk, B., Turk, D. & Turk, V. Lysosomal cysteine proteases: more than scavengers. Biochim. Biophys. Acta 1477, 98–111 (2000).
Bevec, T., Stoka, V., Pungercic, G., Dolenc, I. & Turk, V. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L. J. Exp. Med. 183, 1331–1338 (1996).
Nature Publishing Group. Signalling scissors: new perspectives on proteases [online], (2004).
Research in the Turk laboratory is supported by grants from Slovene Research Agency. I wish to thank primarily G. Salvesen for numerous discussions, similar way of thinking and permission to use information and figures from his summary of the Horizon Symposium 'Signalling scissors: new perspectives on proteases' (see Further information). Also thanks to H. P. Nestler for providing most of the data for Table 1, G. Guncˇar for help with figure preparation, D. Turk and V. Turk for valuable discussions and critical reading of the manuscript, and D. Deaton, D. Percival, E. Altmann, R. Thurmond, N. Borkakoti, U. Grabowska, B. Gerhartz, V. Dive, and many others for sharing their data with me. I would also like to acknowledge the authors of the other ∼300,000 papers found in Medline using protease/proteolysis/proteinase as keywords, whose work contributed to our current understanding of proteolysis but could not have been cited here because of space limitations.
The author declares no competing financial interests.
A zymogen or pro-enzyme is an inactive enzyme precursor. A zymogen requires a biochemical change (such as a hydrolysis reaction revealing the active site, or changing the conformation to reveal the active site) for it to become an active enzyme.
The proteolytic conversion of a zymogen protease molecule into its mature form by molecules of the same kind.
- Extracellular matrix degradation
The extracellular matrix are non-celullar components of tissues, and are primarily composed of various glycoproteins, proteoglycans and hyaluronic acid. In various disease states such as cancer and osteoarthritis, ECM is degraded by various proteases, including matrix metalloproteases and the cathepsins.
- Positional scanning library
A combinatorial chemistry approach in which individual positions in the molecule are kept defined with the other positions being degenerate to yield 'positional libraries'. These compound mixtures are then tested. The most active moieties of the defined (and therefore known) positions are subsequently combined to yield the screening result, the active molecule.
- Mature protease
The catalytically active form of a protease that results from proteolytic processing of its zymogen (inactive pro-enzyme).
A reactive functional group, which covalently binds to amino-acid residues of the target enzyme.
About this article
Cite this article
Turk, B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5, 785–799 (2006). https://doi.org/10.1038/nrd2092
This article is cited by
Gut microbial β-glucuronidases regulate host luminal proteases and are depleted in irritable bowel syndrome
Nature Microbiology (2022)
Ultrafast one-minute electronic detection of SARS-CoV-2 infection by 3CLpro enzymatic activity in untreated saliva samples
Nature Communications (2022)
Nature Communications (2022)
Molecular and Cellular Biochemistry (2022)
Journal of Genetic Engineering and Biotechnology (2021)